We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-15.04%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$185M
AUM Growth
-$43.2M
Cap. Flow
+$19.8M
Cap. Flow %
10.73%
Top 10 Hldgs %
66.67%
Holding
76
New
13
Increased
20
Reduced
16
Closed
22
Avg Time Held Equity + Options
0.6 years
Top 10 Avg Time Held Equity + Options
0.4 years
Top 20 Avg Time Held Equity + Options
0.6 years
Avg Time Held Equity only
0.6 years
Top 10 Avg Time Held Equity only
0.5 years
Top 20 Avg Time Held Equity only
0.6 years

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$9.46M
2
ZGNX
Zogenix, Inc.
ZGNX
+$5.9M
3
RCM icon
R1 RCM Inc. Common Stock
RCM
+$5.74M
4
AERI
Aerie Pharmaceuticals
AERI
+$5.26M
5
AMRN icon
Amarin Corp
AMRN
+$4.88M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$7.55M
2
SAGE icon
Sage Therapeutics
SAGE
+$4.05M
3
ABT icon
Abbott
ABT
+$3.07M
4
MDT icon
Medtronic
MDT
+$2.65M
5
ANAB icon
AnaptysBio
ANAB
+$2.25M

Sector Composition

Rank Sector Weight
1 Healthcare 87.02%
2 Industrials 10.11%
3 Miscellaneous 2.35%
4 Real Estate 0.52%
5 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ZGNX
1
DELISTED
Zogenix, Inc.
ZGNX
$20.5M 11.12%
563,429
+144,150
+34% +$5.9M
2017 Q4
4 quarters
GSK icon
2
GSK
GSK
$99.4B
$20.4M 11.04%
423,587
+192,160
+83% +$9.46M
2018 Q1
3 quarters
RCM icon
3
DELISTED
R1 RCM Inc. Common Stock
RCM
$18.7M 10.11%
2,349,306
+664,219
+39% +$5.74M
2017 Q4
4 quarters
AMRN icon
4
Amarin Corp
AMRN
$241M
$17.2M 9.31%
63,170
+13,385
+27% +$4.88M
2018 Q1
3 quarters
SNY icon
5
Sanofi
SNY
$96.6B
$13.3M 7.2%
306,242
+25,370
+9% +$1.12M
2017 Q4
4 quarters
RDUS icon
6
DELISTED
Radius Health, Inc.
RDUS
$9.1M 4.93%
552,053
+23,061
+4% +$388K
2017 Q4
4 quarters
AERI
7
DELISTED
Aerie Pharmaceuticals
AERI
$8.4M 4.55%
232,790
+112,079
+93% +$5.26M
2017 Q4
4 quarters
VRTX icon
8
Vertex Pharmaceuticals
VRTX
$129B
$6.05M 3.27%
36,492
-11,600
-24% -$2.01M
2017 Q4
4 quarters
DHR icon
9
Danaher
DHR
$161B
$4.94M 2.67%
53,923
+13,762
+34% +$1.25M
2018 Q3
1 quarter
ABMD
10
DELISTED
Abiomed Inc
ABMD
$4.53M 2.45%
13,939
+10,520
+308% +$3.65M
2017 Q4
4 quarters
SRPT icon
11
Sarepta Therapeutics
SRPT
$1.87B
$4.42M 2.39%
40,494
-1,700
-4% -$213K
2018 Q2
2 quarters
VTRS icon
12
CALL
Viatris
VTRS
$21.1B
$4.35M 2.35%
+158,600
New +$5.14M
2018 Q4
0 quarters
ARGX icon
13
argenx
ARGX
$51.9B
$3.67M 1.99%
38,224
+14,670
+62% +$1.3M
2017 Q4
4 quarters
MRK icon
14
Merck
MRK
$362B
$3.53M 1.91%
47,998
-106,896
-69% -$7.55M
2018 Q3
1 quarter
ENSG icon
15
The Ensign Group
ENSG
$10.4B
$3.32M 1.8%
91,480
-52,466
-36% -$2.04M
2017 Q4
4 quarters
ARNA
16
DELISTED
Arena Pharmaceuticals Inc
ARNA
$3.17M 1.72%
81,371
-38,000
-32% -$1.49M
2018 Q1
3 quarters
TLGT
17
DELISTED
Teligent, Inc
TLGT
$3.08M 1.67%
224,748
+13,538
+6% +$354K
2017 Q4
4 quarters
TSRO
18
DELISTED
TESARO, Inc.
TSRO
$2.67M 1.45%
+36,000
New +$1.73M
2018 Q4
0 quarters
ABT icon
19
Abbott
ABT
$182B
$2.27M 1.23%
31,400
-43,700
-58% -$3.07M
2018 Q1
3 quarters
FATE icon
20
Fate Therapeutics
FATE
$228M
$2.12M 1.15%
+165,000
New +$2.3M
2018 Q4
0 quarters
QGEN icon
21
Qiagen
QGEN
$9.55B
$1.91M 1.03%
+52,151
New +$1.94M
2018 Q4
0 quarters
ILMN icon
22
Illumina
ILMN
$39.4B
$1.54M 0.84%
+5,292
New +$1.64M
2018 Q4
0 quarters
GHDX
23
DELISTED
Genomic Health, Inc.
GHDX
$1.54M 0.83%
+23,866
New +$1.67M
2018 Q4
0 quarters
VTRS icon
24
Viatris
VTRS
$21.1B
$1.51M 0.82%
+55,000
New +$1.78M
2018 Q4
0 quarters
DCPH icon
25
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$1.46M 0.79%
+69,700
New +$1.71M
2018 Q4
0 quarters
1
2 3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q4 2018 Portfolio in Review

As of Q4 2018, Eversept Partners held 76 positions worth $185M, down 19% from $228M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Eversept Partners deployed $19.8M of net new capital in Q4 2018, opening 13 new positions and adding to 20 existing holdings. Its largest new stake was Fate Therapeutics: 165,000 shares worth $2.12M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 79% a quarter earlier, followed by Industrials and Miscellaneous.

On the sell side, the largest reduction was Merck, an estimated $7.55M trimmed.

  • Eversept Partners's largest Q4 2018 buy was Fate Therapeutics: 165,000 shares worth $2.12M.
  • Eversept Partners added most to GSK in Q4 2018, an estimated $9.46M increase.
  • Eversept Partners's biggest Q4 2018 reduction was Merck, cutting an estimated $7.55M.
  • Eversept Partners fully exited Medtronic in Q4 2018, selling an estimated $2.65M.
  • Eversept Partners's ten largest holdings make up 67% of its $185M portfolio in Q4 2018.
  • Eversept Partners opened 13 new positions and closed 22 in Q4 2018.
  • Eversept Partners's portfolio value fell 19% quarter-over-quarter to $185M.

Based on Eversept Partners's 13F filing for Q4 2018, filed 13 Feb 2019.